September 24, 2021 06:22 AM EDTUpdated 05:37 PM

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals

With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

Copy Chief

Editor

Sign up to read this article for free.

more like this

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech